NCT01004224
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01004224
Title A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA | TUR | NLD | ITA | ISR | FRA | ESP | DEU | AUT | AUS

Facility Status City State Zip Country Details
Novartis Investigative Site Duarte California 91010 3000 United States Details
Novartis Investigative Site Los Angeles California 90033 United States Details
Novartis Investigative Site Los Angeles California 90095 United States Details
University of Colorado Dept. of Anschutz Cancer (3) Aurora Colorado 80045 United States Details
Novartis Investigative Site New Haven Connecticut 06520 United States Details
Novartis Investigative Site Boston Massachusetts 02114 United States Details
Novartis Investigative Site Detroit Michigan 48201 United States Details
Memorial Sloan Kettering Cancer Center Onc. Dept.. New York New York 10021 United States Details
Novartis Investigative Site New York New York 10029 United States Details
Novartis Investigative Site Columbus Ohio 43221 United States Details
Novartis Investigative Site Philadelphia Pennsylvania 19104 United States Details
Thomas Jefferson University Hospital Onc Dept Philadelphia Pennsylvania 19107-5098 United States Details
Novartis Investigative Site Pittsburgh Pennsylvania 15232 United States Details
Novartis Investigative Site Memphis Tennessee 38120 United States Details
Novartis Investigative Site Nashville Tennessee 37203 United States Details
Novartis Investigative Site Salt Lake City Utah 84103 United States Details
Novartis Investigative Site Heidelberg Victoria 3084 Australia Details
Novartis Investigative Site Vienna A-1100 Austria Details
Novartis Investigative Site Bordeaux 33075 France Details
Novartis Investigative Site Lyon 69373 France Details
Novartis Investigative Site Marseille 13273 France Details
Novartis Investigative Site Montpellier 34298 France Details
Novartis Investigative Site Paris 75015 France Details
Novartis Investigative Site Saint-Herblain Cédex 44805 France Details
Novartis Investigative Site Suresnes 92150 France Details
Novartis Investigative Site Toulouse 31059 France Details
Novartis Investigative Site Villejuif 94805 France Details
Novartis Investigative Site Cologne North Rhine-Westphalia 50937 Germany Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Hanover 30625 Germany Details
Novartis Investigative Site Marburg 35039 Germany Details
Novartis Investigative Site Ramat Gan 5265601 Israel Details
Novartis Investigative Site Tel Aviv 6423906 Israel Details
Novartis Investigative Site Meldola FC 47014 Italy Details
Novartis Investigative Site Amsterdam 1066 CX Netherlands Details
Novartis Investigative Site Amsterdam 1081 HV Netherlands Details
Novartis Investigative Site Singapore 169610 Singapore Details
Novartis Investigative Site Seoul Korea 05505 South Korea Details
Novartis Investigative Site Seoul 03080 South Korea Details
Novartis Investigative Site Seville Andalusia 41013 Spain Details
Novartis Investigative Site Barcelona Catalonia 08035 Spain Details
Novartis Investigative Site Valencia Valencia 46009 Spain Details
Novartis Investigative Site Barcelona 08041 Spain Details
Novartis Investigative Site Madrid 28009 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Madrid 28050 Spain Details
Novartis Investigative Site Taipei 10048 Taiwan Details
Novartis Investigative Site Bangkok 10330 Thailand Details
Novartis Investigative Site Chiang Mai 50200 Thailand Details
Novartis Investigative Site Izmir 35040 Turkey (Türkiye) Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field